Text Size

Pharmacokinetic Investigation of UDCA in Bile and Serum

This study has been completed.
Sponsor:
Information provided by:
Dr. Falk Pharma GmbH
ClinicalTrials.gov Identifier:
NCT00529009
First received: September 12, 2007
Last updated: May 5, 2010
Last verified: May 2010
History of Changes
  Purpose

To assess the bile acid composition of cystic bile and serum pharmaco¬kinetics after a 3-week treatment with UDCA and to correlate pharmacokinetic parameters of UDCA in bile and serum during steady state.


Condition Intervention Phase
Healthy
 Drug: UDCA
 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label

Further study details as provided by Dr. Falk Pharma GmbH:

Study Start Date: May 2007
Detailed Description:

see protocol

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • PBC or healthy

Exclusion Criteria:

  • pathology which does interfere with safety or PK of UDCA
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00529009

Locations
Netherlands
Beuers
Amsterdam, Netherlands
Sponsors and Collaborators
Dr. Falk Pharma GmbH
Investigators
Study Chair: Ulrich Beuers, MD VU University of Amsterdam
  More Information

No publications provided

Responsible Party: Dr. Falk Pharma GmbH
ClinicalTrials.gov Identifier: NCT00529009     History of Changes
Other Study ID Numbers: URT-14/BIO
Study First Received: September 12, 2007
Last Updated: May 5, 2010
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Dr. Falk Pharma GmbH:
PK analysis

ClinicalTrials.gov processed this record on May 16, 2013